Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease

Neurobiology of Aging

Volumn 36, Issue 9, 2015, Pages 2468-2474

  Wilcock, Donna M ^a   Hurban, Jennifer ^a   Helman, Alex M ^a,b   Sudduth, Tiffany L ^a   McCarty, Katie L ^a   Beckett, Tina L ^a,b   Ferrell, Joshua C ^a   Murphy, M Paul ^a,b   Abner, Erin L ^a,b   Schmitt, Frederick A ^a   Head, Elizabeth ^a,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c NONE   (United States)

Author keywords

Alzheimer's disease; Cytokines; Dementia; Down syndrome; Inflammation; Microglia

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CD86 ANTIGEN; FC RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MANNOSE RECEPTOR; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); CYTOKINE; HLA DR ANTIGEN; PEPTIDE FRAGMENT;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOPSY; CELL STIMULATION; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOWN SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTAL CORTEX; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MICROGLIA; MIDDLE AGED; NERVOUS SYSTEM INFLAMMATION; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; WESTERN BLOTTING; YOUNG ADULT; ADOLESCENT; BRAIN; CASE CONTROL STUDY; COMPLICATION; ENCEPHALITIS; GENETICS; METABOLISM; PATHOLOGY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; BRAIN; CASE-CONTROL STUDIES; CYTOKINES; DISEASE PROGRESSION; DOWN SYNDROME; ENCEPHALITIS; FEMALE; HLA-DR ANTIGENS; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PHENOTYPE; YOUNG ADULT;

EID: 84940467398     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.05.016     Document Type: Article

References (38)

1. Alzheimer A., Stelzmann R.A., Schnitzlein H.N., Murtagh F.R. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin. Anat. 1995, 8:429-431.
2. Aydin M., Kabakus N., Balci T.A., Ayar A. Correlative study of the cognitive impairment, regional cerebral blood flow, and electroencephalogram abnormalities in children with Down's syndrome. Int. J. Neurosci. 2007, 117:327-336.
3. Beckett T.L., Niedowicz D.M., Studzinski C.M., Weidner A.M., Webb R.L., Holler C.J., Ahmed R.R., LeVine H., Murphy M.P. Effects of nonsteroidal anti-inflammatory drugs on amyloid-beta pathology in mouse skeletal muscle. Neurobiol. Dis. 2010, 39:449-456.
4. Biskup S., Mueller J.C., Sharma M., Lichtner P., Zimprich A., Berg D., Wullner U., Illig T., Meitinger T., Gasser T. Common variants of LRRK2 are not associated with sporadic Parkinson's disease. Ann. Neurol. 2005, 58:905-908.
5. Cabrejo L., Guyant-Marechal L., Laquerriere A., Vercelletto M., De la Fourniere F., Thomas-Anterion C., Verny C., Letournel F., Pasquier F., Vital A., Checler F., Frebourg T., Campion D., Hannequin D. Phenotype associated with APP duplication in five families. Brain 2006, 129(Pt 11):2966-2976.
6. Cenini G., Dowling A.L., Beckett T.L., Barone E., Mancuso C., Murphy M.P., Levine H., Lott I.T., Schmitt F.A., Butterfield D.A., Head E. Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim. Biophys. Acta 2012, 1822:130-138.
7. Colton C.A., Wilcock D.M. Assessing activation states in microglia. CNS Neurol. Disord. Drug Targets 2009, 9:174-191.
8. Deb S., de Silva P.N., Gemmell H.G., Besson J.A., Smith F.W., Ebmeier K.P. Alzheimer's disease in adults with Down's syndrome: the relationship between regional cerebral blood flow equivalents and dementia. Acta Psychiatr. Scand. 1992, 86:340-345.
9. Edwards J.P., Zhang X., Frauwirth K.A., Mosser D.M. Biochemical and functional characterization of three activated macrophage populations. J.Leukoc. Biol. 2006, 80:1298-1307.
10. Gehrmann J., Banati R.B., Kreutzberg G.W. Microglia in the immune surveillance of the brain: human microglia constitutively express HLA-DR molecules. J.Neuroimmunol. 1993, 48:189-198.
11. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953-964.
12. Griffin W.S., Barger S.W. Neuroinflammatory cytokines-the common thread in Alzheimer's pathogenesis. US Neurol. 2010, 6:19-27.
13. Hyman B.T., Phelps C.H., Beach T.G., Bigio E.H., Cairns N.J., Carrillo M.C., Dickson D.W., Duyckaerts C., Frosch M.P., Masliah E., Mirra S.S., Nelson P.T., Schneider J.A., Thal D.R., Thies B., Trojanowski J.Q., Vinters H.V., Montine T.J. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012, 8:1-13.
14. Johannsen P., Christensen J.E., Mai J. The prevalence of dementia in Down syndrome. Dementia 1996, 7:221-225.
15. Korenberg J.R., Kawashima H., Pulst S.M., Ikeuchi T., Ogasawara N., Yamamoto K., Schonberg S.A., West R., Allen L., Magenis E., Ikawa K., Taniguchi N., Epstein C.J. Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype. Am. J. Hum. Genet. 1990, 47:236-246.
16. Lejeune J., Turpin R., Gautier M. [Mongolism; a chromosomal disease (trisomy)]. Bull. Acad. Natl. Med. 1959, 143:256-265.
17. Leverenz J.B., Raskind M.A. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp. Neurol. 1998, 150:296-304.
18. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
19. Lott I.T. The neurology of Alzheimer disease in Down syndrome. Prog. Clin. Biol. Res. 1992, 379:1-14.
20. Mandrekar-Colucci S., Landreth G.E. Microglia and inflammation in Alzheimer's disease. CNS Neurol. Disord. Drug Targets 2010, 9:156-167.
21. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677-686.
22. Martin S.B., Dowling A.L., Lianekhammy J., Lott I.T., Doran E., Murphy M.P., Beckett T.L., Schmitt F.A., Head E. Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease. J.Alzheimers Dis. 2014, 42:767-775.
23. McGeer P.L., McGeer E.G. Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis. Assoc. Disord. 1998, 12(Suppl 2):S1-S6.
24. Mendel T., Bertrand E., Szpak G.M., Stepien T., Wierzba-Bobrowicz T. Cerebral amyloid angiopathy as a cause of an extensive brain hemorrhage in adult patient with Down's syndrome - a case report. Folia Neuropathol. 2010, 48:206-211.
25. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
26. Mrak R.E., Griffin W.S. Trisomy 21 and the brain. J.Neuropathol. Exp. Neurol. 2004, 63:679-685.
27. Sansom D.M., Manzotti C.N., Zheng Y. What's the difference between CD80 and CD86?. Trends Immunol. 2003, 24:314-319.
28. Sarsoza F., Saing T., Kayed R., Dahlin R., Dick M., Broadwater-Hollifield C., Mobley S., Lott I., Doran E., Gillen D., Anderson-Bergman C., Cribbs D.H., Glabe C., Head E. Afibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol. 2009, 118:505-517.
29. Schmitt A.B., Buss A., Breuer S., Brook G.A., Pech K., Martin D., Schoenen J., Noth J., Love S., Schroder J.M., Kreutzberg G.W., Nacimiento W. Major histocompatibility complex class II expression by activated microglia caudal to lesions of descending tracts in the human spinal cord is not associated with a T cell response. Acta Neuropathol. 2000, 100:528-536.
30. Schupf N., Sergievsky G.H. Genetic and host factors for dementia in Down's syndrome. Br. J. Psychiatry 2002, 180:405-410.
31. Streit W.J., Graeber M.B., Kreutzberg G.W. Functional plasticity of microglia: a review. Glia 1988, 1:301-307.
32. Sudduth T.L., Greenstein A., Wilcock D.M. Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti-Aβ antibodies. J.Neurosci. 2013, 33:9684-9692.
33. Sudduth T.L., Schmitt F.A., Nelson P.T., Wilcock D.M. Neuroinflammatory phenotype in early Alzheimer's disease. Neurobiol. Aging 2013, 34:1051-1059.
34. Taylor P.R., Gordon S., Martinez-Pomares L. The mannose receptor: linking homeostasis and immunity through sugar recognition. Trends Immunol. 2005, 26:104-110.
35. Wilcock D.M. Neuroinflammation in the aging Down syndrome brain; lessons from Alzheimer's disease. Curr. Gerontol. Geriatr. Res. 2012, 2012:170276.
36. Wilcock D.M., Griffin W.S. Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J.Neuroinflammation 2013, 10:84.
37. Wilcock D.M., Lewis M.R., Van Nostrand W.E., Davis J., Previti M.L., Gharkholonarehe N., Vitek M.P., Colton C.A. Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J.Neurosci. 2008, 28:1537-1545.
38. Wisniewski K.E., Wisniewski H.M., Wen G.Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 1985, 17:278-282.